Charles Schwab’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,000
| Closed | -$339K | – | 3505 |
|
|
2025
Q4 | $339K | Hold |
10,000
| – | – | ﹤0.01% | 3251 |
|
|
2025
Q3 | $258K | Hold |
10,000
| – | – | ﹤0.01% | 3323 |
|
|
2025
Q2 | $80K | Sell |
10,000
-8,868
| -47% | -$67.6K | ﹤0.01% | 3423 |
|
|
2025
Q1 | $184K | Buy |
18,868
+9,996
| +113% | +$98.3K | ﹤0.01% | 3269 |
|
|
2024
Q4 | $112K | Buy |
8,872
+4
| +0% | +$51 | ﹤0.01% | 3389 |
|
|
2024
Q3 | $143K | Sell |
8,868
-17,149
| -66% | -$347K | ﹤0.01% | 3362 |
|
|
2024
Q2 | $635K | Sell |
26,017
-3,440
| -12% | -$159K | ﹤0.01% | 3095 |
|
|
2024
Q1 | $2.12M | Buy |
29,457
+152
| +0.5% | +$21.1K | ﹤0.01% | 2575 |
|
|
2023
Q4 | $5.83M | Buy |
29,305
+1,581
| +6% | +$196K | ﹤0.01% | 2243 |
|
|
2023
Q3 | $3.69M | Buy |
27,724
+2,993
| +12% | +$489K | ﹤0.01% | 2391 |
|
|
2023
Q2 | $3.7M | Buy |
24,731
+360
| +1% | +$56.1K | ﹤0.01% | 2354 |
|
|
2023
Q1 | $3.58M | Buy |
24,371
+2,973
| +14% | +$601K | ﹤0.01% | 2348 |
|
|
2022
Q4 | $3.39M | Buy |
21,398
+587
| +3% | +$93.9K | ﹤0.01% | 2395 |
|
|
2022
Q3 | $4.01M | Buy |
20,811
+1,759
| +9% | +$333K | ﹤0.01% | 2330 |
|
|
2022
Q2 | $2.78M | Buy |
19,052
+825
| +5% | +$110K | ﹤0.01% | 2451 |
|
|
2022
Q1 | $3.21M | Buy |
18,227
+468
| +3% | +$88.4K | ﹤0.01% | 2482 |
|
|
2021
Q4 | $5.22M | Buy |
17,759
+242
| +1% | +$64.7K | ﹤0.01% | 2326 |
|
|
2021
Q3 | $4.35M | Buy |
17,517
+7,422
| +74% | +$1.96M | ﹤0.01% | 2440 |
|
|
2021
Q2 | $2.57M | Buy |
10,095
+1,845
| +22% | +$345K | ﹤0.01% | 2627 |
|
|
2021
Q1 | $1.47M | Sell |
8,250
-43
| -0.5% | -$7.09K | ﹤0.01% | 2732 |
|
|
2020
Q4 | $1.31M | Buy |
8,293
+118
| +1% | +$25.7K | ﹤0.01% | 2700 |
|
|
2020
Q3 | $2.11M | Buy |
8,175
+1,705
| +26% | +$378K | ﹤0.01% | 2478 |
|
|
2020
Q2 | $1.5M | Buy |
6,470
+2,766
| +75% | +$428K | ﹤0.01% | 2514 |
|
|
2020
Q1 | $631K | Buy |
3,704
+1,679
| +83% | +$382K | ﹤0.01% | 2632 |
|
|
2019
Q4 | $448K | Buy |
+2,025
| New | +$373K | ﹤0.01% | 2861 |
|
Charles Schwab's RAPT Position: Q1 2026 in Review
Charles Schwab sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 10,000 shares — an estimated $339K sold.
Charles Schwab first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $5.83M in Q4 2023. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Charles Schwab reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Charles Schwab sold 10,000 RAPT Therapeutics shares in Q1 2026, an estimated $339K.
- Charles Schwab first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- Charles Schwab's RAPT Therapeutics position peaked at $5.83M in Q4 2023.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.